Amgen Inc
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen IMDELLTRA / IMDYLLTRA (tarlatamab-dlle by Quarter
IMDELLTRA / IMDYLLTRA (tarlatamab-dlle — DLL3 BiTE, Small Cell Lung Cancer) — Rest of World (ROW) product sales ($M) ($M)
Amgen IMDELLTRA / IMDYLLTRA (tarlatamab-dlle: $55M in Q2 2026, up 103.7% from a year earlier.
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-05) ↗
Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | IMDELLTRA / IMDYLLTRA (tarlatamab-dlle — DLL3 BiTE, Small Cell Lung Cancer) — Rest of World (ROW) product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 55 | +103.7% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 70 | +3,400.0% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2025 | Dec 31, 2025 | 51 | – | Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗ |
| Q3 2025 | Sep 30, 2025 | 34 | – | Form 8-K (amgn-20250930earningsrelea.htm, filed 2025-11-04) ↗ |
| Q2 2025 | Jun 30, 2025 | 27 | – | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 2 | – | Form 10-Q (filed 2026-05-01) ↗ |
Cite this data
StockData. (2026). Amgen IMDELLTRA / IMDYLLTRA (tarlatamab-dlle ($M), quarterly Q1 2025–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-imdelltra-row
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.